Navigation Links
EAU launches new clinical guidelines for 2009 -- kidney cancer
Date:3/17/2009

Arnhem, The Netherlands A number of updated guidelines will be presented at the 24th Annual Congress of the European Association of Urology (EAU) held in Stockholm, from 17 though 21 March. The abridged versions - Pocket Guidelines which are based on the extended text documents will also be available in Stockholm to all EAU members and press.

Production of clinical guidelines is one of the core activities of the organisation. Close to 150 experts split up over 18 different topic-oriented panels, are involved in this ongoing process. Guidelines aim to present the best evidence available on a given pathology and provide a standardized approach to the treatment of urological conditions. Ultimately, healthcare professionals must make their own decisions about care on a case-by-case basis, after consultation with their patients, using their clinical judgment, knowledge and expertise.

Kidney Cancer

Due to the enhanced use of imaging techniques over the past years a stage shift has been seen in the field of renal cell cancer with a volume increase in the incidental detection of smaller cancers (< 4 cm). Thirty percent of these findings are benign. The treatment of metastatic small tumours show a decrease in death rates. A considerable portion of these tumours can be treated with nephron sparing surgery. Additionally, a number of targeted agents have become available with several more expected shortly.

The panel updated these Kidney Cancer guidelines since for several targeted agents more mature data have been published and validated prognostic nomograms predicting treatment outcome accuracy are available for more treatment options.

The panel do not recommend Interferon-alpha (IFN-alpha) in a first-line setting as monotherapy in the treatment of metastatic RCC. Sunitinib and Bevacizumab + IFN-alpha are recommended as first-line therapy in low- and intermediate-risk patients while

Temsirolimus is recommended for high risk patients; Sorafenib and Everolimus can be recommended as second-line therapy after cytokine and tyrosine kinase inhibitor (TKI) failure, respectively.

The expectation is that further targeted agents will be on the market shortly. Also the role of molecular medicine in the treatment of renal cell carcinoma will become more prominent. A subsequent update will take this information in, once sufficiently data is available.

The panel consists of an expert group chaired by B. Ljungberg and includes D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard and I.C. Sinescu.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. MIT scientist launches special nanoscience symposia at ACS National Meeting
2. ESA launches first Earth Explorer mission GOCE
3. HRSA Launches Online Resource to Help Prevent Poisonings
4. HealthyPlace.com, the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
5. Cardinal Health Launches New Products for the Operating Room
6. GeoFitness Launches Get Moving America Campaign to Improve Youth Health
7. Health Integrated Launches Unique Service for Health Plans Preparing for Federal Mental Health Parity Regulations
8. Confidential Listening Service We Just Listen Launches, Providing Americans a Private Platform to Express Their Thoughts and Feelings
9. eCardio Diagnostics Launches Academic Medicine Initiative
10. MorseLife Launches Learning Institute to Teach Best Practices in Leadership, Healthcare and Kosher Culinary
11. ADA Launches Community Dental Health Coordinator Program to Provide Dental Care in Underserved Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
(Date:6/23/2016)... 2016  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member.  ... vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, ... NPC Board of Directors. ... joined us in support of our efforts to ...
Breaking Medicine Technology: